Related Experiment Video

Updated: Apr 28, 2026

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.2K

Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment

Do-Young Choi1, Sungyong You, Jae Hun Jung

  • 1Department of Applied Chemistry, College of Applied Science, Kyung Hee University, Yongin, Republic of Korea.

Proteomics
|June 20, 2014
PubMed

Insights

Gefitinib resistance in non-small cell lung cancer involves specific extracellular vesicle (EV) protein signatures. Targeting the AKT/mTOR pathway in EVs can overcome this resistance, offering new diagnostic and therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Non-small cell lung cancer (NSCLC) treatment often involves epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) like gefitinib for patients with activating EGFR mutations.
  • Acquired resistance to EGFR-TKIs is a significant clinical challenge, limiting long-term treatment efficacy.
  • Identifying mechanisms of resistance is crucial for developing effective therapeutic strategies.

Purpose of the Study:

  • To identify protein signatures in extracellular vesicles (EVs) from gefitinib-resistant NSCLC cells.
  • To investigate the role of these EV protein signatures in mediating drug resistance.
  • To explore potential therapeutic targets for overcoming gefitinib resistance.

Main Methods:

  • Proteomics analysis using Nano-LC-MS/MS to identify EV proteins.
  • Computational analysis to identify overrepresented signaling pathways.
  • In vitro experiments treating recipient cells with EVs and assessing drug resistance and signaling pathway activation.
  • Pharmacological inhibition of the AKT/mTOR pathway.

Main Results:

  • 664 EV proteins were identified as enriched in gefitinib-resistant PC9R cells (EGFR T790M mutation).
  • The AKT/mTOR signaling pathway was found to be overrepresented in EVs from resistant cells.
  • EVs from resistant cells promoted recipient cell proliferation, invasion, and gefitinib resistance.
  • Inhibition of the AKT/mTOR pathway overcame gefitinib resistance in resistant NSCLC cells.

Conclusions:

  • Extracellular vesicles carry oncogenic protein signatures that contribute to gefitinib resistance in NSCLC.
  • The AKT/mTOR pathway plays a critical role in mediating EV-driven drug resistance.
  • These findings suggest novel diagnostic markers and therapeutic targets for predicting and overcoming gefitinib resistance.
Keywords:
AKTCell biologyExtracellular vesiclesNonsmall cell lung cancermTOR signaling pathway

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K